(Q37813524)
Statements
1 reference
Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review (English)
1 reference
Katherine Tyner
1 reference
Nakissa Sadrieh
1 reference
1 January 2011
1 reference
1 reference
697
1 reference
17-31
1 reference
Identifiers
1 reference
1 reference